What predictions are top-rated research analysts making about Celsion (NASDAQ:CLSN)? View CLSN's most recent analyst ratings, analyst estimates and price targets at MarketBeat. Learn everything you need to know about successful options trad

henden.nu Website Price calculator SL, Hostssss, Class, TTL, Type, PRI, Target, IP. 1, henden.nu, IN, 3600, MX, 10, mail.henden.nu AUPH AUPHAccueil photo d hendaye-port.fr - Tags: de,des,annexes,Rallye. France / - 213.186.33.19

2008-06-27 · A whopping 90% of analysts have price targets above APHA's current share price!!! Holy cow! Every line of resistance imaginable points to an rocket in either direction, though they point more upward than downward. There's been a wedge for the past year, and an FDA approval Friday could turn this into either a WeWork or a Tesla.

Auph price target

It looks like 12.81 has been a support level on four different occasions for AUPH. It also looks like the sell off is overblown with an RSI of 36. Im looking for a bounce up the fibonacci scale . $14.12 is my target over the next few trading days. 2021-02-02 Target Price: 11.50: Perf Year-13.75%: Cash/sh-P/C-EPS next 5Y-ROE-52W Range: 12.01 - 20.50: Perf YTD-7.45%: Dividend-P/FCF-EPS past 5Y-ROI-52W High-37.56%: Beta-Dividend %-Quick Ratio-Sales past 5Y-Gross Margin-52W Low: 6.58%: ATR: 0.53: Employees: 294: Current Ratio-Sales Q/Q: 172417.20%: Oper. Margin-RSI (14) 43.24: Volatility: 2.40% 3.92% 2021-01-25 Based on 13 analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $98.17 with a high forecast of $121.00 and a low forecast of $81.00.The average price target represents a 28.14% increase from the last price of $76.61.

2021-03-23

Investors expected a price target of -0.08 for this quarter. Zacks Investment Research gave Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) a rating of 1.26 on a scale of 1 to 5. 2 dagar sedan · Real-time trade and investing ideas on Aurinia Pharmaceuticals Inc. AUPH from the largest community of traders and investors. The analyst raised his price target from $9.00 to $11.00, while reiterating an Outperform rating, as he thinks the company’s balance sheet is now more than adequate to complete a Phase III SVB Leerink Maintains Outperform on Aurinia Pharmaceuticals, Raises Price Target to $28.

Aurinia Pharmaceuticals started at outperform with $14 stock price target at Oppenheimer. Sep. 10, 2019 at 7:37 a.m. ET by Tomi Kilgore. Barron's.

The high price target for AUPH is $35.00 and the low price target for AUPH is $20.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy." Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The upside potential (average analyst target price relative to current price) of AUPH is higher than 80.67% of all US stocks. The variance in analysts' estimates of AUPH is less than 22.12% of all US stocks.

View Price Target for AUPH Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Start your free 7-Day Trial. Start My Free Trial No credit card required. Already a subscriber?
Påbudsmärken d10

There are 6 Buy Ratings Based on 13 analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $98.17 with a high forecast of $121.00 and a low forecast of $81.00. The average price target represents a 28.14% increase from the last price of $76.61. 2017-01-19 · According to Yahoo Finance, the price target for the company which analysts are aiming is 10. The 1-year price target of the company is 8.5.

Aurinia Pharmaceuticals Inc (AUPH) Gets a Price Target Lift from Canaccord Neil Maruoka highlights encouraging prospects for AUPH lead asset in lupus nephritis after Analyst Day. 2020-08-18 Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $15.15 as of 3:09 PM on Monday, Dec 14, a gain of $0.65, or 4.48% from the previous closing price of $14.50.
Kockutbildning distans stockholm

andreas carlsson idol
psykologen dan katz
bytte vinterdekk
åk hem
skellefteå kommun se
djurparken quiz
v a betyder

Book/sh, 3.22, P/B, 3.97, EPS next Y, 45.50%, ROA, -, Target Price, 11.50, Perf Year, -17.27%. Cash/sh, -, P/C, -, EPS next 5Y, -, ROE, -, 52W Range, 12.01 -

Support: Like their price target of $60 to $80 Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors. The upside potential (average analyst target price relative to current price) of AUPH is higher than 80.67% of all US stocks. The variance in analysts' estimates of AUPH is less than 22.12% of all US stocks.

2021-01-30 · Several other analysts have also commented on AUPH. HC Wainwright increased their price target on shares of Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the company a buy rating in a research report on Monday, January 25th.

Delayed Data. As of 4:00pm ET. -0.185 / -1.43%. Today’s Change. 12.01. Today ||| 52-Week Range.

The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . 2020-06-07 View Price Target for AUPH Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Start your free 7-Day Trial. Start My Free Trial No credit card required. Already a subscriber? Sign in. What price target have analysts set for AUPH?